<DOC>
	<DOCNO>NCT01677871</DOCNO>
	<brief_summary>During Study : - Subject require visit every week first 2 month every month till completion study require - The usual symptomatic supportive treatment Chronic Liver Disease , include use antiviral , give patient . - Effort make avoid use hepatotoxic drug ( ) Anti-Tubercular Treatment . - Liver function test ( LFT ) do weekly first 2 month one month interval require . - The treatment efficacy Anti-Tubercular Treatment ( ATT ) make basis clinical , biochemical , microbiological image parameter month 2 , 4 , 7 9 . Patients improve 4 week initiation treatment shift alternative regimen exclude study .</brief_summary>
	<brief_title>Efficacy Safety Modified Anti-tubercular Regimens Treatment Tuberculosis Patients With Underlying Compensated Decompensated Chronic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<criteria>Males Females subject age 1875 year . Subjects chronic liver disease ( cirrhosis ) Pulmonary extrapulmonary tuberculosis . Serum ALT≤5times upper limit serum bilirubin ≤3 mg/dl . consent willingness followup Serum ALT &gt; 5times upper limit serum bilirubin &gt; 3 mg/dl . Renal failure ( serum creatinine &gt; 2mg/dl ) . Presence hepatocellular carcinoma Alcoholic cirrhotic continue drink alcohol . Prior history ATT ( ANTI TUBERCULAR TREATMENT ) document hepatotoxicity . Known hypersensitivity levofloxacin , quinolones</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>